Oral Oncology Reports最新文献

{"title":"Head and neck squamous cell carcinoma epidemiology at diagnosis: A description of public and private health care systems in Brazil regarding tumor location, staging and risk factors","authors":"Heloisa Arantes ,&nbsp;Diego Chaves Rezende Morais ,&nbsp;Maria Aparecida do Carmo Rego ,&nbsp;Paula de Mendonça Batista ,&nbsp;Cicera Pimenta Marcelino ,&nbsp;Milena Falcão Almeida ,&nbsp;Marion Coting Braga ,&nbsp;Paula Cristina Pungartnik ,&nbsp;Angelica Carreira dos Santos ,&nbsp;Juliana Ominelli ,&nbsp;Tharcísio Machado Coelho ,&nbsp;Fernanda Bohns Pruski Ramos ,&nbsp;Marcelo Salgado ,&nbsp;Marina Kelner ,&nbsp;Cristiano Guedes Duque ,&nbsp;Daniel Oliveira Brito ,&nbsp;Carlos Gil Moreira Ferreira ,&nbsp;Pedro Rafael Martins De Marchi","doi":"10.1016/j.oor.2024.100645","DOIUrl":"10.1016/j.oor.2024.100645","url":null,"abstract":"<div><h3>Objectives</h3><p>There is a limited number of updated epidemiological Brazilian data on head and neck squamous cell carcinoma (HNSCC). This study aimed to describe demographic and clinical characteristics of HNSCC patients from Brazilian public and private systems.</p></div><div><h3>Methods</h3><p>This is a retrospective observational study that included patients diagnosed with HNSCC from Brazilian public and private settings from 2016 to 2018. As for the public scenario, data were drawn from the public hospital national cancer registry database. As for the private sector, the data were extracted from medical records of patients from Oncoclinicas, a large Brazilian oncology group.</p></div><div><h3>Results</h3><p>A total of 37,121 patients were included in the study, with 36,914 from the public and 207 from the private system. Patients in the public sector were younger than those in the private sector, with medians ages of 61.2 and 66.9 years, respectively. In both cohorts, a predominance of men with a history of tobacco and alcohol consumption and an advanced locoregional stage at diagnosis was observed. The main site of the primary tumor was the oropharynx in the private sector and oral cavity in the public sector. Among patients with oropharyngeal cancer, only those in the private sector were tested for HPV, with the majority being positive.</p></div><div><h3>Conclusions</h3><p>This real-world data study provides epidemiologic characteristics of patients with HNSCC in two different Brazilian healthcare settings, presenting relevant insights into possible opportunities for improvements in the patient's journey with HNSCC.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100645"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004916/pdfft?md5=3753b590b326c428beeb02e8c820046a&pid=1-s2.0-S2772906024004916-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142228830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological risk factors of oral second primary tumours","authors":"Jelena Karan ,&nbsp;Miriam P. Rosin ,&nbsp;Lewei Zhang ,&nbsp;Denise M. Laronde","doi":"10.1016/j.oor.2024.100638","DOIUrl":"10.1016/j.oor.2024.100638","url":null,"abstract":"<div><h3>Background</h3><p>Oral second primary tumours (SPTs) have a poor prognosis due to late-stage diagnosis. This study evaluates the demographic and clinicopathological risk predictors of SPTs.</p></div><div><h3>Methods</h3><p>Patients with oral squamous cell carcinoma, carcinoma in situ, or severe dysplasia were accrued into the Oral Cancer Prediction Longitudinal study within one year post-curative treatment. Data on demographics, risk habits, and primary tumour characteristics were collected. Clinical follow-up included assessing the presence of second oral premalignant lesions (SOPLs), clinicopathological features, and the results from toluidine blue staining and fluorescence visualization.</p></div><div><h3>Results</h3><p>Among 296 patients, 23 (8 %) developed SPTs. Older age at primary cancer diagnosis (P = 0.008) and a history of chewing tobacco or betel nut (P = 0.043) increased the risk of SPTs. Patients with primary tumours located at low-risk sites had an increased risk of SPTs (P = 0.004), which often presented at high-risk sites. The presence of SOPLs (P &lt; 0.001), and multiple lesions (P = 0.017) significantly increased the risk of SPTs. Positive toluidine blue staining indicated a trend toward higher risk of SPTs, whereas fluorescence visualization did not. The median time to SPT diagnosis was 3.25 years post-treatment.</p></div><div><h3>Conclusions</h3><p>Identifying second or multiple oral premalignant lesions is critical for predicting the risk of SPTs regardless of their clinical or histological characteristics. Routine biopsy of these lesions should be prioritized to ensure timely diagnosis. Incorporating these risk predictors into clinical follow-up can enhance early cancer detection and improve patient outcomes.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100638"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004849/pdfft?md5=828d81ed8c1e6adabae59d42c3182190&pid=1-s2.0-S2772906024004849-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142228831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing programmed death-ligand 1 as a prognostic marker in OSCC: Challenges and opportunities in the era of immunotherapy","authors":"Madhan Krishnan,&nbsp;Shyamaladevi Babu","doi":"10.1016/j.oor.2024.100641","DOIUrl":"10.1016/j.oor.2024.100641","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100641"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004874/pdfft?md5=022251cdec70f75510a2e3fab0a8a2df&pid=1-s2.0-S2772906024004874-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142171618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the gap between epigenetics and cisplatin resistance: Implications for oral cancer management","authors":"Monisha Prasad,&nbsp;Ameerunnisha Begum","doi":"10.1016/j.oor.2024.100649","DOIUrl":"10.1016/j.oor.2024.100649","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100649"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004953/pdfft?md5=c861e29e5c61983140b6670ac2ec7e82&pid=1-s2.0-S2772906024004953-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142228823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolution of blood cancer treatment in the oral cavity: Breakthroughs in nanotherapy","authors":"Pavithra Bharathy,&nbsp;Elizabeth Rani E,&nbsp;Punniyakoti V. Thanikachalam","doi":"10.1016/j.oor.2024.100635","DOIUrl":"10.1016/j.oor.2024.100635","url":null,"abstract":"<div><p>This comprehensive review explores the potential of nanotherapy in the treatment of blood cancers, specifically leukemia, lymphoma, and myeloma, in the oral cavity. Nanoparticles (NPs) made from organic and inorganic materials have shown promise in delivering therapeutic substances to cancer cells, enhancing their pharmacological efficacy, and reducing their systemic toxicity. Different types of nanoparticles, such as liposomes, extracellular vehicles, and polymeric nanoparticles, have been studied for their effectiveness in targeting cancer cells. Nanotherapy has also been investigated for overcoming drug resistance, targeting cancer stem cells, bypassing efflux pumps, and gene silencing. Clinical trials and research findings have demonstrated the potential of nanotherapy for improving outcomes in patients with acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. However, challenges exist in addressing the heterogeneity of blood cancers in the oral cavity, navigating the tumor microenvironment, overcoming drug resistance, and modulating immune evasion. Future directions include individualized treatment plans, multifunctional nanoparticles, combination therapies, and improved nanoparticle design. The translation of these breakthroughs into clinical practice requires collaboration among researchers, physicians, and industry stakeholders. Overall, nanotherapy holds promise for more effective and less invasive treatments for blood cancer in the oral cavity.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100635"},"PeriodicalIF":0.0,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004813/pdfft?md5=6846a22d0efea8706080e366bbb7b6b2&pid=1-s2.0-S2772906024004813-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142089036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in robotic surgery for oral oncology: Enhanced precision and improved outcomes","authors":"Santosh R. Patil","doi":"10.1016/j.oor.2024.100634","DOIUrl":"10.1016/j.oor.2024.100634","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100634"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004801/pdfft?md5=1b094b83ff38ade1b36e5fc2bdeb8a47&pid=1-s2.0-S2772906024004801-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142039677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does altered Ki67 expression in recurrent membranous basal cell adenoma point toward the need for reclassification?","authors":"Dhinakaran Paranchodi,&nbsp;Ashok Vikey,&nbsp;Jaya Joshi,&nbsp;Ramya Selvam,&nbsp;Neha Choudhary","doi":"10.1016/j.oor.2024.100631","DOIUrl":"10.1016/j.oor.2024.100631","url":null,"abstract":"<div><p>The pathogenesis of membranous BCA recurrence remains unclear, with only a few cases reported. The current study focuses on a case that exhibits a high Ki-67 proliferative index, which raises questions about its impact on the prognosis and treatment plan. We have conducted a literature review to gain insight into the altered ki67 expression pattern in membranous BCA. We have also proposed a hypothesis that suggests recurrent membranous BCA cases with Ki67 levels between 5 % and 10 % signify an intermediate grade and warrant reclassification. More research is needed to confirm this hypothesis and understand the prognosis for this variant.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100631"},"PeriodicalIF":0.0,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004771/pdfft?md5=4b84d5ce2885e710f048199ae20a4920&pid=1-s2.0-S2772906024004771-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142021228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of single nucleotide polymorphism of p16 gene in cytological samples of patients with oral potentially malignant disorders (OPMD) and oral squamous cell carcinoma (OSCC)","authors":"Neetu Oommen ,&nbsp;Vasanthi V ,&nbsp;Ramya Ramadoss ,&nbsp;Rajkumar Krishnan","doi":"10.1016/j.oor.2024.100632","DOIUrl":"10.1016/j.oor.2024.100632","url":null,"abstract":"<div><h3>Background</h3><p>pl6 (CDKN2a) play a role in tumorigenesis in some head and neck squamous cell carcinomas. Frequent homozygous deletions of the pl6 gene have been reported in many tumor cell lines including the brain, breast, osteosarcomas, melanomas, kidney, bladder, and ovary.</p></div><div><h3>Materials and methods</h3><p>5 patients without any tobacco using habit were included in group I as controls. 10 clinically and histopathologically confirmed cases of oral potentially malignant disorders (OPMDs) [oral submucous fibrosis (OSMF) −7 &amp; leukoplakia (moderate dysplasia) −3] were included in group II. 10 clinically and histopathologically confirmed cases of OSCC were categorized as group III. Buccal scrapings were taken and analyzed for exon 1, 2, 3 of p16 and homozygous deletion in exon 2 of p16 was also detected by PCR and gel electrophoresis.</p></div><div><h3>Results</h3><p>PCR amplification products of exon 1, 2, 3 of p16 were found in all 25 samples which include 10 cases of OSCC, 10 cases of OPMDs and 5 controls. Homozygous deletion in exon 2 was found only in 30 % of OSCC and 20 % of OPMD.</p></div><div><h3>Conclusion</h3><p>Our study showed that cytological samples yield sufficient amount of DNA, which showed 100 % positivity with exon 1, 2, 3 of p16 gene, but the percentage of genetic alteration of p16 gene seems to be less when compared with other related studies.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100632"},"PeriodicalIF":0.0,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004783/pdfft?md5=1abb5db1bf3ed21f7f5470bfc79d0195&pid=1-s2.0-S2772906024004783-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nivolumab (Opdivo) in PD-1 pathway inhibition: Enhancing immune response in recurrent oral squamous cell carcinoma","authors":"Nandhini J.,&nbsp;Karthikeyan E.","doi":"10.1016/j.oor.2024.100630","DOIUrl":"10.1016/j.oor.2024.100630","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100630"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277290602400476X/pdfft?md5=4395debc01eb9459fda6417ac9290b74&pid=1-s2.0-S277290602400476X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preserving academic integrity in the age of AI: Ethical guidelines for medical manuscript preparation","authors":"Amit Medhekar,&nbsp;Amarnath Gupta,&nbsp;Smita Sonawane,&nbsp;Meenakshi Singh","doi":"10.1016/j.oor.2024.100627","DOIUrl":"10.1016/j.oor.2024.100627","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100627"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004734/pdfft?md5=4abe224268021f3b52faa61b17037595&pid=1-s2.0-S2772906024004734-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}